You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
|
|---|---|
| Published in |
Annals of Oncology, January 2014
|
| DOI | 10.1093/annonc/mdt369 |
| Pubmed ID | |
| Authors |
P.S. Grimison, M.R. Stockler, M. Chatfield, D.B. Thomson, V. Gebski, M. Friedlander, A.L. Boland, B. Houghton, H. Gurney, M. Rosenthal, N. Singhal, G. Kichenadasse, S.S. Wong, C.R. Lewis, P.A. Vasey, G.C. Toner, Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
| Abstract |
This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerability and activity of accelerated bleomycin, etoposide and cisplatin (BEP) as first-line chemotherapy for metastatic germ cell tumours. |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ethiopia | 1 | 4% |
| Italy | 1 | 4% |
| Ecuador | 1 | 4% |
| Spain | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 22 | 81% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 19% |
| Student > Bachelor | 5 | 19% |
| Other | 4 | 15% |
| Researcher | 4 | 15% |
| Student > Postgraduate | 2 | 7% |
| Other | 4 | 15% |
| Unknown | 3 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 63% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Agricultural and Biological Sciences | 1 | 4% |
| Physics and Astronomy | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 5 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2014.
All research outputs
#17,286,379
of 25,374,917 outputs
Outputs from Annals of Oncology
#6,169
of 7,854 outputs
Outputs of similar age
#202,815
of 319,281 outputs
Outputs of similar age from Annals of Oncology
#100
of 136 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,281 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 136 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.